FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057488389> ?p ?o ?g. }

• W2057488389 endingPage "62" @default.
• W2057488389 startingPage "62.1" @default.
• W2057488389 abstract "<h3>Background</h3> Interleukin (IL)-1β plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, has been shown to be efficacious in the treatment of SJIA.¹ <h3>Objectives</h3> To analyze gene expression and inflammatory proteins in blood of SJIA patients (pts) on CAN therapy.To identify biomarkers that predict clinical response to CAN treatment at baseline. <h3>Methods</h3> Inflammatory protein biomarkers (IL-6; IL-18) and gene expression profiles of active SJIA pts (aged 2 to <20 yrs) before and during CAN or placebo treatment in 2 phase III trials were analyzed. Gene expression patterns were also compared to those in a healthy control group. <h3>Results</h3> <i>Gene expression</i>: Changes upon CAN treatment at Day 3 were assessed. Using identical filtering criteria (≥2 fold, p≤0.05), no CAN responsive genes were found for placebo (n=9) or for CAN (n=11) treated pts that were non-responders (adapted pediatric [ACR]30 not achieved) at Day 15. In contrast, 171 probesets passed this filter for responder pts (n=52, ≥ACR30), all of whom received CAN. Strongly repressed genes included many inflammation- and innate immunity-related genes (eg, IL-1β, IL1R1, IL1R2, TLR1, TLR4, TLR5). A set of transcripts was identified for which high baseline expression levels predicted a majority of strong (≥ACR50) responders. However, baseline transcript levels of a second, smaller subgroup of strong CAN responders, were similar to ACR30 responders and non-responders which in turn resembled levels found in healthy controls (n=22). Upon CAN treatment, transcript levels largely returned to those resembling healthy controls in the majority of strong responders. <i>Protein markers</i>: IL-6 protein levels were reduced by Day 3 (-4.7x and -4.4x with p=0.002 and 0.0001, n=20 and n=51 for the respective 2 trials), and at Day 29 (-12.5x and -8.1x with p=0.01 and 0.00005, n=20 and n=65). Greater reduction at Days 3 and 29 was observed for pts with strong Day 15 ACR response. IL-18 levels were mostly unchanged until Day 29 and with only moderate reduction at Day 57. <h3>Conclusions</h3> Canakinumab treatment resulted in a rapid, strong reduction of many pro-inflammatory transcripts and serum IL-6, while IL-18 levels showed a delayed, weaker reduction. A majority of strong treatment responders were characterized by a set of transcripts with high baseline levels which reduced to healthy subject levels with treatment while other strong responders did not show elevation of these transcripts at baseline, suggesting heterogeneity at the molecular level in SJIA pts benefitting from canakinumab. <h3>References</h3> Ruperto N. et al. N Engl J Med 2012;367:2396-406. <h3>Disclosure of Interest</h3> A. Brachat Shareholder of: Novartis, Employee of: Novartis, A. Grom Consultant for: Novartis, Roche, NovImmune, N. Wulffraat Grant/research support: AbbVie, Roche, Consultant for: Novartis, Pfizer, Roche, H. Brunner Consultant for: Novarits, Roche, Astrazeneca, Celgene, Pfizer, Janssen, UCB, GSK, BMS, Speakers bureau: Novartis, P. Quartier Grant/research support: AbbVie, Chigai-Roche, Novartis, Pfizer, Consultant for: Chugai-Roche, Novartis, Pfizer, Speakers bureau: Abbott/AbbVie, BMS, Chugai-Roche, Novartis, Pfizer, Servier, SOBI, R. Brik Grant/research support: Novartis, Consultant for: Novartis, L. McCann: None declared, H. Ozdogan Consultant for: Novartis, L. Rutkowska-Sak: None declared, R. Schneider Consultant for: Novartis, Roche, V. Gerloni: None declared, L. Harel: None declared, M. Terreri: None declared, K. Houghton: None declared, R. Joos: None declared, D. Kingsbury: None declared, J. Lopez-Benitez: None declared, S. Bek Employee of: Novartis, M. Schumacher Employee of: Novartis, M. Valentin Shareholder of: Novartis, Employee of: Novartis, H. Gram Employee of: Novartis, K. Abrams Shareholder of: Novartis, Employee of: Novartis, A. Martini Grant/research support: BMS, Centocor,GSK, Novartis, Pfizer, Roche, Sanofi Aventis, Schwarz Biosciences: To Gaslini Hospital to support PRINTO research, Consultant for: BMS, Centocor,GSK, Novartis, Pfizer, Roche, Sanofi Aventis, Schwarz Biosciences:To Gaslini Hospital to support PRINTO research, Speakers bureau: Abbott, BMS, Astellas, Boehringer, Italfarmaco, MedImmune, Novartis, NovoNordisk, Pfizer, Sanofi Aventis, Roche, Servier, N. Ruperto Grant/research support: Abbott, Astrazeneca, BMS, Centocor, Eli Lilly, Francesco Angelini, GSK, Italfarmaco, Novartis, Pfizer/Wyeth, Roche, Sanofi Aventis, Schwarz Biosciences, Xoma: to Gaslini Hospital, Speakers bureau: Astrazeneca, BMS, Janssen Biologics BV, Roche, Pfizer/Wyeth, D. Lovell Grant/research support: National Institutes of Health-NIAMS, Consultant for: Astra-Zeneca, Centocor, Amgen, Bristol Meyers Squibb, Abbott, Pfizer, Regeneron, Roche, Novartis, UCB, Forest Research Institute, Horizon, Johnson & Johnson, Speakers bureau: Novartis, Roche, N. Nirmala Employee of: Novartis <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2320" @default.
• W2057488389 created "2016-06-24" @default.
• W2057488389 creator A5003805334 @default.
• W2057488389 creator A5007941133 @default.
• W2057488389 creator A5015732937 @default.
• W2057488389 creator A5017146451 @default.
• W2057488389 creator A5027612338 @default.
• W2057488389 creator A5034764312 @default.
• W2057488389 creator A5037853723 @default.
• W2057488389 creator A5040793104 @default.
• W2057488389 creator A5044717717 @default.
• W2057488389 creator A5052603798 @default.
• W2057488389 creator A5055874104 @default.
• W2057488389 creator A5059659054 @default.
• W2057488389 creator A5065461018 @default.
• W2057488389 creator A5066691116 @default.
• W2057488389 creator A5066850130 @default.
• W2057488389 creator A5067099449 @default.
• W2057488389 creator A5068285710 @default.
• W2057488389 creator A5075666115 @default.
• W2057488389 creator A5080140512 @default.
• W2057488389 creator A5080176966 @default.
• W2057488389 creator A5082970356 @default.
• W2057488389 creator A5084611399 @default.
• W2057488389 creator A5087359884 @default.
• W2057488389 creator A5089162243 @default.
• W2057488389 creator A5089949725 @default.
• W2057488389 creator A5091263515 @default.
• W2057488389 date "2014-06-01" @default.
• W2057488389 modified "2023-09-27" @default.
• W2057488389 title "OP0007 Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy" @default.
• W2057488389 doi "https://doi.org/10.1136/annrheumdis-2014-eular.2320" @default.
• W2057488389 hasPublicationYear "2014" @default.
• W2057488389 type Work @default.
• W2057488389 sameAs 2057488389 @default.
• W2057488389 citedByCount "2" @default.
• W2057488389 countsByYear W20574883892015 @default.
• W2057488389 crossrefType "journal-article" @default.
• W2057488389 hasAuthorship W2057488389A5003805334 @default.
• W2057488389 hasAuthorship W2057488389A5007941133 @default.
• W2057488389 hasAuthorship W2057488389A5015732937 @default.
• W2057488389 hasAuthorship W2057488389A5017146451 @default.
• W2057488389 hasAuthorship W2057488389A5027612338 @default.
• W2057488389 hasAuthorship W2057488389A5034764312 @default.
• W2057488389 hasAuthorship W2057488389A5037853723 @default.
• W2057488389 hasAuthorship W2057488389A5040793104 @default.
• W2057488389 hasAuthorship W2057488389A5044717717 @default.
• W2057488389 hasAuthorship W2057488389A5052603798 @default.
• W2057488389 hasAuthorship W2057488389A5055874104 @default.
• W2057488389 hasAuthorship W2057488389A5059659054 @default.
• W2057488389 hasAuthorship W2057488389A5065461018 @default.
• W2057488389 hasAuthorship W2057488389A5066691116 @default.
• W2057488389 hasAuthorship W2057488389A5066850130 @default.
• W2057488389 hasAuthorship W2057488389A5067099449 @default.
• W2057488389 hasAuthorship W2057488389A5068285710 @default.
• W2057488389 hasAuthorship W2057488389A5075666115 @default.
• W2057488389 hasAuthorship W2057488389A5080140512 @default.
• W2057488389 hasAuthorship W2057488389A5080176966 @default.
• W2057488389 hasAuthorship W2057488389A5082970356 @default.
• W2057488389 hasAuthorship W2057488389A5084611399 @default.
• W2057488389 hasAuthorship W2057488389A5087359884 @default.
• W2057488389 hasAuthorship W2057488389A5089162243 @default.
• W2057488389 hasAuthorship W2057488389A5089949725 @default.
• W2057488389 hasAuthorship W2057488389A5091263515 @default.
• W2057488389 hasConcept C126322002 @default.
• W2057488389 hasConcept C142724271 @default.
• W2057488389 hasConcept C203014093 @default.
• W2057488389 hasConcept C204787440 @default.
• W2057488389 hasConcept C27081682 @default.
• W2057488389 hasConcept C2776252253 @default.
• W2057488389 hasConcept C2776914184 @default.
• W2057488389 hasConcept C2777077863 @default.
• W2057488389 hasConcept C2777575956 @default.
• W2057488389 hasConcept C2779134260 @default.
• W2057488389 hasConcept C2779725882 @default.
• W2057488389 hasConcept C2781228260 @default.
• W2057488389 hasConcept C71924100 @default.
• W2057488389 hasConceptScore W2057488389C126322002 @default.
• W2057488389 hasConceptScore W2057488389C142724271 @default.
• W2057488389 hasConceptScore W2057488389C203014093 @default.
• W2057488389 hasConceptScore W2057488389C204787440 @default.
• W2057488389 hasConceptScore W2057488389C27081682 @default.
• W2057488389 hasConceptScore W2057488389C2776252253 @default.
• W2057488389 hasConceptScore W2057488389C2776914184 @default.
• W2057488389 hasConceptScore W2057488389C2777077863 @default.
• W2057488389 hasConceptScore W2057488389C2777575956 @default.
• W2057488389 hasConceptScore W2057488389C2779134260 @default.
• W2057488389 hasConceptScore W2057488389C2779725882 @default.
• W2057488389 hasConceptScore W2057488389C2781228260 @default.
• W2057488389 hasConceptScore W2057488389C71924100 @default.
• W2057488389 hasIssue "Suppl 2" @default.
• W2057488389 hasLocation W20574883891 @default.
• W2057488389 hasOpenAccess W2057488389 @default.
• W2057488389 hasPrimaryLocation W20574883891 @default.
• W2057488389 hasRelatedWork W1984834472 @default.
• W2057488389 hasRelatedWork W2043790076 @default.
• W2057488389 hasRelatedWork W2077680652 @default.
• W2057488389 hasRelatedWork W2085536696 @default.

• next